| Head injury: assessment and early management | NG232 | | |
| Head injury | QS74 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment | HTE7 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
| Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
| Fasciotens for abdominal wall closure | MIB321 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| Lumasiran for treating primary hyperoxaluria type 1 | HST25 | | |
| Onasemnogene abeparvovec for treating spinal muscular atrophy | HST15 | | |
| Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency | HST26 | | |
| Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | HST24 | | |
| Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea | IPG760 | | |
| Endoscopic ultrasound-guided biliary drainage for biliary obstruction | IPG761 | | |
| Hypertension in pregnancy: diagnosis and management | NG133 | | |
| AposHealth for knee osteoarthritis | MTG76 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Radiofrequency ablation for palliation of painful spinal metastases | IPG758 | | |
| Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases | IPG759 | | |
| Percutaneous thoracic duct embolisation for persistent chyle leak | IPG755 | | |
| Focal therapy using high-intensity focused ultrasound for localised prostate cancer | IPG756 | | |
| Maximal cytoreductive surgery for advanced ovarian cancer | IPG757 | | |
| UrgoStart for treating diabetic foot ulcers and leg ulcers | MTG42 | | |
| Macimorelin for diagnosing growth hormone deficiency | MIB320 | | |
| Acute kidney injury | QS76 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment | HTE4 | | |
| Type 1 diabetes in adults | QS208 | | |
| Type 2 diabetes in adults | QS209 | | |
| Asfotase alfa for treating paediatric-onset hypophosphatasia | HST23 | | |
| Endoluminal gastroplication for gastro-oesophageal reflux disease | IPG753 | | |
| Percutaneous transluminal renal sympathetic denervation for resistant hypertension | IPG754 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene | HST22 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis | MIB317 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |